IMREG-1
Term · Oncology and biomedicine · MLC-T-ONC-014396
A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.
| Identifier | MLC-T-ONC-014396 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | IMREG 1 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014396",
"term": "IMREG-1",
"field": "Oncology and biomedicine",
"definition": "A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.",
"expansions": [
"IMREG 1"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/imreg-1/"
}
Record 9,138 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.